Benign Prostatic HyperplasiaNCT05543200
BPH Global Registry
An observational study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, run by Société Internationale d'Urologie at 30 sites in 21 countries.
Trial summary
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- How many people
- 7,500 participants
- Where
- 30 sitesin 21 countries
- Study dates
- 13 Mar 2023to Dec 2028
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: All patients >18 years with symptomatic BPH with LUTS who are planned for medical or surgical intervention are eligible for this study.
Who may be able to join
- Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention
Who cannot join
- Non-symptomatic BPH
- No treatment prescribed for BPH
Trial locations and contacts
30 sites in 21 countries. Contact the study team or a site near you to ask about taking part.
30 sites in 21 countries
Canada3 sites, 3 recruiting
- Recruiting
McGill University Health Centre
Montreal, Quebec
Mélanie Aubé-Peterkin, MD, melanieaubep@gmail.com
Mélanie Aubé-Peterkin, MD
- Not yet recruiting
University of Montreal Hospital Center
Montreal
Abbas Guennoun, abbas.guennoun.chum@ssss.gouv.qc.ca
Naeem Bhojani, MD
- Recruiting
Toronto Western Hospital, University Health Network
Toronto, Ontario
Iris Chan, Iris.Chan2@uhn.ca
Dean Elterman, MD, MSc, FRCSC
Kenya3 sites, 3 recruiting
- Not yet recruiting
Gracepark Medical Centre
Meru
Elias Nyaga, MD, drnyagaem@gmail.com
Elias Nyaga, MD
- Not yet recruiting
Pandya Memorial Hospital
Mombasa
Sundeep Chavda, MD, schavda@hotmail.com
Sundeep Chavda, MD
- Not yet recruiting
Kenyatta National Hospital
Nairobi
Carnjini Yogeswaran, MD, carnjini@gmail.com
Carnjini Yogeswaran, MD
Chile2 sites, 2 recruiting
- Recruiting
Hospital Dr. Juan Morey La Unión
La Unión
Fernando Segura, MD, fernando.seguradiaz@gmail.com
Fernando Segura, MD
- Recruiting
Hospital del Trabajador
Santiago
Reynaldo Gomez, MD, gomez.reynaldo@gmail.com
Reynaldo Gomez, MD
Italy2 sites, 2 recruiting
- Recruiting
Azienda Ospedaliero-Universitaria Careggi
Florence
Edoardo Dibilio, MD, edoardo.dibilio@unifi.it
Mauro Gacci, MD
- Recruiting
Sapienza University of Rome, Division of Urology, Ospedale Sant'Andrea
Rome
Antonio Nacchia, MD, antonionacchia7@gmail.com
Cosimo De Nunzio, MD, PhD
Nigeria2 sites, 2 recruiting
- Recruiting
Benue State University Teaching Hospital, Department of Surgery
Makurdi
Christian Agbo, MD, agbo535@gmail.com
Christian Agbo, MD
- Recruiting
Ahmadu Bello University Teaching Hospital
Zaria
Nasir Oyelowo, MD, nasiroyelowo@gmail.com
Nasir Oyelowo, MD
Pakistan2 sites, 2 recruiting
- Recruiting
Institute of Kidney Diseases Peshawar
Peshawar
Abdul Haseeb, MD, ahaseeb.dr@gmail.com
Abdul Haseeb, MD
- Recruiting
Lady Reading Hospital
Peshawar
Muhammad Asif, MD, drasif_15@yahoo.com
Muhammad Asif, MD
United Kingdom2 sites, 2 recruiting
- Not yet recruiting
Imperial College Healthcare NHS Trust
London
Ranan Dasgupta, MD
Ranan Dasgupta, MD
- Recruiting
Southend University Hospital
Southend-on-Sea
Daben Dawam, MD, d.dawam@nhs.net
Daben Dawam, MD
United States1 site, 1 recruiting
- Recruiting
Keck Medicine of USC
Los Angeles, California, 90089
Mihir Desai, MD
Mihir Desai, MD
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou
Ben Liu, MD, drliuben@sina.com
Ben Liu, MD
Cyprus1 site, 1 recruiting
- Not yet recruiting
University of Cyprus
Nicosia
Stavros Gravas, MD, Phd, sgravas2002@yahoo.com
Satvros Gravas, MD
Hong Kong1 site, 1 recruiting
- Not yet recruiting
The Chinese University of Hong Kong
Hong Kong
Alex Qinyang Liu, MD, alexliu@surgery.cuhk.edu.hk
Alex Qinyang Liu, MD
India1 site, 1 recruiting
- Recruiting
Dr Baba Saheb Ambedkar Medical College and Hospital
Delhi
Mohammad Shazib Faridi, MD, drshazibfaridi@gmail.com
Mohammad Shazib Faridi, MD
Iran1 site, 1 recruiting
- Recruiting
Shariati Hospital
Tehran
Seyed Reza Yahyazadeh, MD, r.yahyazadeh@gmail.com
Seyed Reza Yahyazadeh, MD
Iraq1 site, 1 recruiting
- Recruiting
University of Basrah
Basra
Murtadha Almusafer, MD, murtadha.majeed@uobasrah.edu.iq
Murtadha Almusafer, MD
Lebanon1 site, 1 recruiting
- Recruiting
American University of Beirut
Beirut
Yara Ghandour, MD, yg10@aub.edu.lb
Albert El Hajj, MD
Malaysia1 site, 1 recruiting
- Recruiting
Universiti Malaya
Kuala Lumpur
Shanggar Kuppusamy, MD, PhD, shanggar@ummc.edu.my
Shanggar Kuppusamy, MD, PhD
Mali1 site, 1 recruiting
- Recruiting
Kati University Hospital
Kati
Idrissa Sissoko, MD, idrississoko@gmail.com
Idrissa Sissoko, MD
Mexico1 site, 1 recruiting
- Recruiting
Centro Medico Nacional Siglo XXI
Mexico City
Laura Coretta Mejia Rios, MD, dralau.coretta@gmail.com
Laura Coretta Mejia Rios, MD
Qatar1 site, 1 recruiting
- Recruiting
Hamad Medical Corporation Qatar
Doha
Kamran Bhatti, MD, kamibhatti92@gmail.com
Kamran Bhatti, MD
South Korea1 site, 1 recruiting
- Not yet recruiting
Seoul National University Bundang Hospital
Seongnam
Sang Hun Song, MD, shsong@snubh.org
Sung Kyu Hong, MD
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Istanbul Medipol University
Istanbul
Bulent Erkurt, MD, berkurt@medipol.edu.tr
Bulent Erkurt, MD
About this study
Official title: A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.
Read the detailed description
Due to a growing and aging population, cases of benign prostatic hyperplasia (BPH) have been on a steady rise. Studies show that by age 80, 90% of men experience BPH. (Garraway, Lee, Collins, 1991) Thus, treatment of BPH is one of the most performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been somewhat standardized. The purpose of this study is to create an ongoing prospective registry to record demographic data and clinical outcomes after medical therapy or different surgical interventions for BPH. The specific aims of the registry are to analyze demographic patterns and baseline characteristics of men undergoing surgical and medical treatments for BPH, to assess global practice patterns for various surgical and medical treatments of BPH, and to assess key outcomes for uni- and multi-modal treatments of BPH.
The ongoing global registry will provide important baseline data, functional outcomes, and complications following medical and/or surgical intervention for men with symptomatic BPH. The intention of the registry is to provide real world usage data that may be used for future investigations. It will allow providers to identify areas of interest, areas of unusually low usage or areas of unusual preference on a global scale. It will also shed light on global preferences for unimodal or multimodal approaches to treatments.
The registry has been developed using novel database technology, providing an easy-to-use user interface, which enables future creation of patient portals and Electronic Medical Record (EMR) integration.
As this is not an experimental setting, there will be no interventions made on behalf of the registry.
This is a prospective longitudinal ongoing registry. The study will include medical records of all men ≥18 years old who have a primary diagnosis of BPH with Lower Urinary Tract Symptoms (LUTS) that are prescribed BPH medications, or a surgical intervention. Data extraction includes baseline data, peri-operative data, and follow-up data. Baseline data includes validated patient reported outcome tools, including International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD), as well as Quality of Life (QoL), maximum flow rate (Qmax), Post-void residual (PVR), Prostate Specific Antigen (PSA), and Testosterone. Complications such as Bleeding, Urinary Tract Infection (UTI), Incontinence, Stricture, Retrograde ejaculation, and Erectile Dysfunction (ED) are also tracked from Baseline through Follow-up.
The registry will run for 3 years with no end point for follow-up. For three years, various research studies will be formulated, and the results will be published. The possibility of extending the study for continued follow-up will be evaluated.
A built-in quality control using data validation during the input process decreases the chance that invalid data will be entered or that datapoints will be omitted. Periodic audits will be performed to verify accuracy of source data by our audit committee based on our audit committee guidelines.
Records and cases of all men with a primary diagnosis of BPH with LUTS that are prescribed BPH medications, or a surgical intervention will be identified and included in the registry. All data is hashed (i.e., protected from decryption) except for a medical record number (MRN), which will be used to add follow-up data to the patient's record. This number is encrypted and linked to the hashed and randomly generated institution code. For security purposes, biographical information is not saved on the registry.
The registry provides secure access to registered users using a web browser. Registrations are site-specific, which means that users can only access the data that is specific to their own site. The registry application and databases are hosted on secure, encrypted servers behind a firewall. They can only be accessed by registered users via a specific port.
- Keywords
- BPH, Registry, LUTS
- Medical subject headings
- Prostatic Hyperplasia, Lower Urinary Tract Symptoms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| All Participants | All men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
International Prostate Symptom Score (IPSS)
Comparison of mean IPSS score change between baseline and at each follow-up during the course of the study. The scale goes from 0 (Mild) to 35 (Severe).
Measured: 36 months
Quality of Life (QoL)
Comparison of mean QoL score change between baseline and at each follow-up during the course of the study. The scale is a single question which ranges from 0 to 6, with higher numbers indicating a worse quality of life.
Measured: 36 months
Post-Void Residual (PVR)
Comparison of mean PVR change between baseline and at each follow-up during the course of the study.
Measured: 36 months
Complications (including incontinence)
Type and Clavien grade incidences across all surgical interventions.
Measured: 36 months
Secondary outcomes (4)
Prostate Volume (cc)
Comparison of mean Prostate Volume change between baseline and at each follow-up during the course of the study.
Measured: 36 months
Qmax
Comparison of mean Qmax change between baseline and at each follow-up during the course of the study.
Measured: 36 months
Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD)
Comparison of mean MSHQ-EjD score change between baseline and at each follow-up during the course of the study. The scale ranges from 1 to 15 with a higher score indicating better sexual functioning.
Measured: 36 months
Sexual Health Inventory for Men (SHIM)
Comparison of mean SHIM score change between baseline and at each follow-up during the course of the study.
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2022
- Study start13 Mar 2023
- Primary completionDec 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Benign Prostatic HyperplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 7,500 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Société Internationale d'Urologie
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mihir Desai, MD, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05543200
- Sponsor's protocol ID
- uCARE-2022-001
- Status last verified
- Aug 2026
- First submitted
- 13 Sep 2022
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia
- ClinicalTrials.gov ID
- NCT05543200
- Acronym / sponsor ID
- uCARE-2022-001
- Keywords
- BPH, Registry, LUTS
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 7,500 participants (estimated)
- Lead sponsor
- Société Internationale d'UrologieUniversity, hospital or other
- Study start
- 13 Mar 2023 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 16 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.
Detailed description
Due to a growing and aging population, cases of benign prostatic hyperplasia (BPH) have been on a steady rise. Studies show that by age 80, 90% of men experience BPH. (Garraway, Lee, Collins, 1991) Thus, treatment of BPH is one of the most performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been somewhat standardized. The purpose of this study is to create an ongoing prospective registry to record demographic data and clinical outcomes after medical therapy or different surgical interventions for BPH. The specific aims of the registry are to analyze demographic patterns and baseline characteristics of men undergoing surgical and medical treatments for BPH, to assess global practice patterns for various surgical and medical treatments of BPH, and to assess key outcomes for uni- and multi-modal treatments of BPH.
The ongoing global registry will provide important baseline data, functional outcomes, and complications following medical and/or surgical intervention for men with symptomatic BPH. The intention of the registry is to provide real world usage data that may be used for future investigations. It will allow providers to identify areas of interest, areas of unusually low usage or areas of unusual preference on a global scale. It will also shed light on global preferences for unimodal or multimodal approaches to treatments.
The registry has been developed using novel database technology, providing an easy-to-use user interface, which enables future creation of patient portals and Electronic Medical Record (EMR) integration.
As this is not an experimental setting, there will be no interventions made on behalf of the registry.
This is a prospective longitudinal ongoing registry. The study will include medical records of all men ≥18 years old who have a primary diagnosis of BPH with Lower Urinary Tract Symptoms (LUTS) that are prescribed BPH medications, or a surgical intervention. Data extraction includes baseline data, peri-operative data, and follow-up data. Baseline data includes validated patient reported outcome tools, including International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD), as well as Quality of Life (QoL), maximum flow rate (Qmax), Post-void residual (PVR), Prostate Specific Antigen (PSA), and Testosterone. Complications such as Bleeding, Urinary Tract Infection (UTI), Incontinence, Stricture, Retrograde ejaculation, and Erectile Dysfunction (ED) are also tracked from Baseline through Follow-up.
The registry will run for 3 years with no end point for follow-up. For three years, various research studies will be formulated, and the results will be published. The possibility of extending the study for continued follow-up will be evaluated.
A built-in quality control using data validation during the input process decreases the chance that invalid data will be entered or that datapoints will be omitted. Periodic audits will be performed to verify accuracy of source data by our audit committee based on our audit committee guidelines.
Records and cases of all men with a primary diagnosis of BPH with LUTS that are prescribed BPH medications, or a surgical intervention will be identified and included in the registry. All data is hashed (i.e., protected from decryption) except for a medical record number (MRN), which will be used to add follow-up data to the patient's record. This number is encrypted and linked to the hashed and randomly generated institution code. For security purposes, biographical information is not saved on the registry.
The registry provides secure access to registered users using a web browser. Registrations are site-specific, which means that users can only access the data that is specific to their own site. The registry application and databases are hosted on secure, encrypted servers behind a firewall. They can only be accessed by registered users via a specific port.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All Participants | – | –All men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients >18 years with symptomatic BPH with LUTS who are planned for medical or surgical intervention are eligible for this study.
Key inclusion criteria (1 listed)
- Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention
Key exclusion criteria (2 listed)
- Non-symptomatic BPH
- No treatment prescribed for BPH
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
International Prostate Symptom Score (IPSS)
Time frame: 36 months
Comparison of mean IPSS score change between baseline and at each follow-up during the course of the study. The scale goes from 0 (Mild) to 35 (Severe).
Quality of Life (QoL)
Time frame: 36 months
Comparison of mean QoL score change between baseline and at each follow-up during the course of the study. The scale is a single question which ranges from 0 to 6, with higher numbers indicating a worse quality of life.
Post-Void Residual (PVR)
Time frame: 36 months
Comparison of mean PVR change between baseline and at each follow-up during the course of the study.
Complications (including incontinence)
Time frame: 36 months
Type and Clavien grade incidences across all surgical interventions.
4 secondary outcomes
Prostate Volume (cc)
Time frame: 36 months
Qmax
Time frame: 36 months
Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD)
Time frame: 36 months
Sexual Health Inventory for Men (SHIM)
Time frame: 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Home pageLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Benign Prostatic Hyperplasia
Not yet recruiting
Anterior Bridge-Preserving Versus Conventional Early Apical Release in Bipolar Enucleation of the Prostate
Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
Not yet recruitingPhase 3
Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Not yet recruiting
Anterior Bridge-Preserving Versus Conventional Early Apical Release During Holmium Laser Enucleation of the Prostate
Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
Recruiting
Learning Curve of Tri-lobar HoLEP Versus En-bloc HoLEP
Benign Prostatic Hyperplasia With Outflow Obstruction
RecruitingObservational study
Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong
Benign Prostatic Hyperplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mihir Desai, MD principal investigator
University of Southern California
30 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, run by Société Internationale d'Urologie at 30 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in Canada, Kenya, Chile, Italy, Nigeria and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mihir Desai, MD (+1 (323) 865 3700, mihir.desai@med.usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
International Prostate Symptom Score (IPSS) (time frame: 36 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.